How much funding has NeoTract raised?

NeoTract has raised $36.8M in total funding, most recently a Series F round.

Who are NeoTract's investors?

NeoTract's investors include Teleflex, Johnson & Johnson Innovation, NEA, Windham Venture Partners.

Where is NeoTract headquartered?

NeoTract is headquartered in Pleasanton, California, United States.

What industry is NeoTract in?

NeoTract operates in Healthcare, Medical Devices, Medtech.

NeoTract

Acquired

Minimally invasive solutions for urological conditions.

Pleasanton, United States · Founded 2004 · $36.8M raised

Healthcare

Medical Devices

Medtech

Headquarters: Pleasanton, California
Employees: 51–200
Founded: 2004
Business Model: B2B

Website: urolift.com
Total Funding: $36.8M
Last Round: $12.8M Series FJan 2016
Rounds: 7

About

NeoTract was a privately-held medical device company headquartered in Pleasanton, California, focused on addressing unmet needs in urology. Founded in 2004 by Ted Lamson and Joseph Catanese, the company developed and commercialized the FDA-cleared UroLift System — a minimally invasive permanent implant that treats lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) while preserving sexual function. The UroLift System became a widely adopted alternative to medications and major surgery for enlarged prostate. NeoTract was acquired by Teleflex in October 2017 for up to $1.1 billion ($725M upfront plus up to $375M in milestone payments).

Summary

NeoTract is a Healthcare company based in Pleasanton, United States, founded in 2004. It has raised $36.8M in total across 7 rounds, most recently a $12.8M Series F round in Jan 2016. Investors include Teleflex, Johnson & Johnson Innovation and NEA.

LinkedIn X (Twitter)